Population Pharmacokinetics of Adalimumab in Juvenile Idiopathic Arthritis Patients: A Retrospective Cohort Study Using Clinical Care Data-Reference-Cited by-同舟云学术

Population Pharmacokinetics of Adalimumab in Juvenile Idiopathic Arthritis Patients: A Retrospective Cohort Study Using Clinical Care Data

Published:2024-04-17 Issue:4 Volume:26 Page:441-450
ISSN:1174-5878
Container-title:Pediatric Drugs
language:en
Short-container-title:Pediatr Drugs

Author:

Nassar-Sheikh Rashid Amara^ORCID,Hooijberg Femke,Bergkamp Sandy C.,Gruppen Mariken P.,Kuijpers Taco W.,Nurmohamed Mike,Rispens Theo,Wolbink Gertjan,van den Berg J. Merlijn,Schonenberg-Meinema Dieneke,Mathôt Ron A. A.

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40272-024-00629-7.pdf

Reference44 articles.

1. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377(9783):2138–49. https://doi.org/10.1016/S0140-6736(11)60244-4.

2. Angeles-Han ST, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis. Arthritis Care Res (Hoboken). 2019;71(6):703–16. https://doi.org/10.1002/acr.23871.

3. Gregory AC 2nd, et al. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the SITE study. Ophthalmology. 2013;120(1):186–92. https://doi.org/10.1016/j.ophtha.2012.07.052.

4. Giancane G, Ruperto N, O. Paediatric Rheumatology International Trials. Treatment of juvenile idiopathic arthritis: what’s new? Curr Opin Rheumatol. 2019;31(5):428–35. https://doi.org/10.1097/BOR.0000000000000632.

5. Giancane G, et al. Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era. Arthritis Res Ther. 2019;21(1):168. https://doi.org/10.1186/s13075-019-1950-7.